Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Mar;28(3):179–184. doi: 10.1007/BF00204986

Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models

Thomas Reissmann 1,✉, Rainer Voegeli 1, Jörg Pohl 1, Peter Hilgard 1
PMCID: PMC11038858  PMID: 2924329

Abstract

By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically.

The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells.

Keywords: Cyclophosphamide, Spleen Cell, L5222 Cell, Adoptive Transfer, Antitumor Immunity

Footnotes

Supported by the Federal Ministry of Research and Technology (BMFT), Bonn-Bad Godesberg, FRG

References

  • 1.Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 1982;42:4862. [PubMed] [Google Scholar]
  • 2.Berd D, Maguire HC, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 1984;44:1275. [PubMed] [Google Scholar]
  • 3.Chang AE, Shu S, Chou T. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 1986;46:3426. [PubMed] [Google Scholar]
  • 4.Druckrey H, Steinhoff D, Nakayama M. Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch Med Wschr. 1963;88:10. [Google Scholar]
  • 5.El-Sady E, Parker D, Turk IL. The effect of cyclophosphamide in vivo on the expression of lymphocyte markers, detected by monoclonal antibodies in the rat. Int J Immunopharmacol. 1986;8:961. doi: 10.1016/0192-0561(86)90098-6. [DOI] [PubMed] [Google Scholar]
  • 6.Feldmann IP. Immunological enhancement: a study of blocking antibodies. Adv Immunol. 1972;15:167. doi: 10.1016/s0065-2776(08)60685-9. [DOI] [PubMed] [Google Scholar]
  • 7.Hanna N, Borton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol. 1981;127:1754. [PubMed] [Google Scholar]
  • 8.Hoon DS, Ramshaw IA. Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor. Cancer Immunol Immunother. 1985;20:175. doi: 10.1007/BF00205685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ivankovic S, Zeller W. Leukämie L5222 des Rattenstammes BD IX. Eine durch Aethylnitrosoharnstoff induzierte monozytäre-myeloische, transplantierbare Form für zytochemische und chemotherapeutische Studien. Blut. 1974;28:288. doi: 10.1007/BF01631649. [DOI] [PubMed] [Google Scholar]
  • 10.L'Age-Stehr J, Diamantstein T. Induction of autoreative T-lymphocytes and their suppressor cells by cyclophosphamide. Nature. 1987;271:663. doi: 10.1038/271663a0. [DOI] [PubMed] [Google Scholar]
  • 11.LeGrue SI, Simcik WI, Frost P. Immunogenic variants of a murine fibrosarcoma induced by mutagenesis: requirement of viable cells for antigen-specific cross-protection. Cancer Res. 1987;47:4413. [PubMed] [Google Scholar]
  • 12.Lotze MT, Grimm EA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420. [PubMed] [Google Scholar]
  • 13.Mihich E. Immunomodulation by anticancer agents. Proc Am Assoc Cancer Res. 1988;29:517. [Google Scholar]
  • 14.Mitsuoka A, Baba M, Morikawa S. Enhancement of delayed hypersensitivity by depletion of suppressor T-cells with cyclophosphamide in mice. Nature. 1976;262:77. doi: 10.1038/262077a0. [DOI] [PubMed] [Google Scholar]
  • 15.Mokyr MB, Barker E. Specificity of the generation and expression of enhanced anti-plasmocytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. Cancer Immunol Immunother. 1986;18:41. doi: 10.1007/BF00205549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mokyr MB, Braun DP, Dray S. Augmentation of antitumor cytotoxicity in MOPC-315 tumor-bearer spleen cells by depletion of glass-adherent cells prior to in vitro education. Cancer Res. 1979;39:785. [PubMed] [Google Scholar]
  • 17.Mokyr MB, Colvin M, Dray S. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmacol. 1985;7:111. doi: 10.1016/0192-0561(85)90016-5. [DOI] [PubMed] [Google Scholar]
  • 18.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  • 19.Noar D. Suppressor cells: permitters and promoters of malignancy? Adv Cancer Res. 1979;29:45. doi: 10.1016/s0065-230x(08)60846-5. [DOI] [PubMed] [Google Scholar]
  • 20.Ozer H, Cowens IW, Colvin M. In vitro effects of 4-hydroperoxy-cyclophosphamide on human immunoregulatory T subset function. J Exp Med. 1982;155:276. doi: 10.1084/jem.155.1.276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Peppoloni S, Mathieson BI, Herberman RB. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets. Cancer Immunol Immunother. 1987;24:49. doi: 10.1007/BF00199832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pohl J, Reissmann T, Voegeli R. Oxazaphosphorine effect in L5222 rat leukemia. Methods Find Exp Clin Pharmacol. 1987;9:589. [PubMed] [Google Scholar]
  • 23.Prehn RT, Main IN. Immunity to methylcholanthrene-induced sarkomas. J Natl Cancer Inst. 1957;18:769. [PubMed] [Google Scholar]
  • 24.Schlick E, Hewetson P, Ruffmann R. Adjuvant Chemoimmunotherapy of cancer: influence of tumor-burden and role of functional immune effector cells in mice. Cancer Res. 1986;46:3378. [PubMed] [Google Scholar]
  • 25.Tamura K, Shibata Y. Isolation and characterization of an immunosuppressive acidic protein from ascites fluids of cancer patients. Cancer Res. 1981;41:3244. [PubMed] [Google Scholar]
  • 26.Young MR, Newby M. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice. J Natl Cancer Inst. 1986;77:1255. [PubMed] [Google Scholar]
  • 27.Young MR, Wheeler E, Newby M. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J Natl Cancer Inst. 1986;76:745. doi: 10.1093/jnci/76.4.745. [DOI] [PubMed] [Google Scholar]
  • 28.Zeller WJ, Schmalenberger B, Pohl J, Bartkowski R, Zankl H. Different chemotherapeutic sensitivity of two L5222 leukemia lines in relation to immunogenicity and cytogenetics. J Cancer Res Clin Oncol. 1983;105:A36. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES